{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-006739","form_type":"8-K","ticker":"MXCT","cik":"0001287098","company_name":"MAXCYTE, INC.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.842139+00:00","generated_at":"2026-05-22T07:14:59.308068+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"MaxCyte Q1 2025 revenue down 8% to $10.4M; reiterates FY2025 guidance","bullets":["Total revenue $10.4M (-8% YoY); core revenue $8.2M (+1%); SPL program revenue $2.1M (-32%).","Net loss $10.3M vs $9.5M in Q1 2024; cash $174.7M as of March 31, 2025.","Added one SPL client (TG Therapeutics); total active SPLs now 29.","Reiterates FY2025: core revenue growth 8-15%, SPL program revenue ~$5M, ending cash ~$160M.","Integration of SeQure Dx ongoing; management cites robust SPL pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-006739","json":"https://secwatch.observer/filing/0001558370-25-006739.json","markdown":"https://secwatch.observer/filing/0001558370-25-006739.md","text":"https://secwatch.observer/filing/0001558370-25-006739.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1287098/000155837025006739/0001558370-25-006739-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1287098/000155837025006739/mxct-20250507x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T07:14:59.308068+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}